Skip to main content

Market Overview

Galectin Therapeutics Stock Is Trading Higher After Belapectin-Pembrolizumab Combo Study Shows Enhanced Tumor Response

Share:
Galectin Therapeutics Stock Is Trading Higher After Belapectin-Pembrolizumab Combo Study Shows Enhanced Tumor Response
  • Galectin Therapeutics Inc (NASDAQ: GALT) has announced that a paper in the peer-reviewed Journal for ImmunoTherapy of Cancer (JITC) published data from an ongoing Phase 1 trial evaluating Galectin's belapectin in head & neck cancer, lung cancer, and melanoma.
  • The study assessing belapectin combined with Merck's & Co's (NYSE: MRK) Keytruda (pembrolizumab) is being conducted to collaborate between Galectin and Providence Cancer Institute in Portland.
  • As previously disclosed, an objective response of 50% in advanced metastatic melanoma and 33% in head and neck squamous cell carcinoma patients was observed in the study.
  • It compares favorably to published response rates on pembrolizumab alone.
  • The publication also noted that the combination was associated with fewer immune-mediated adverse events than anticipated with pembrolizumab alone.
  • Besides, the patient's tumor tissue analysis showed reduced monocytic myeloid-derived suppressor cells and increased effector memory T-cell activation in responders compared with non-responders.
  • An increase in baseline expression of galectin-3 positive tumor cells correlated with clinical response was also seen.
  • Belapectin (GR-MD-02) is a complex carbohydrate drug that targets galectin-3, a critical protein in NASH and fibrosis's pathogenesis. The company believes Galectin-3 has a significant role in cancer as well.
  • The drug candidate binds to galectin-3 and disrupts its function.
  • Price Action: GALT shares are up 24.3% at $2.69 in the premarket session on the last check Wednesday.
 

Related Articles (MRK + GALT)

View Comments and Join the Discussion!

Posted-In: Briefs cancer Solid TumorBiotech News Penny Stocks Health Care General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com